

To: (10)(2e) (10)(2e) @rivm.nl; (10)(2e) (10)(2e) @rivm.nl
From: (10)(2e)
Sent: Fri 9/11/2020 12:59:16 PM
Subject: FW: COVID-19: verslag EU Executive Steering Group - 9 september 2020
Received: Fri 9/11/2020 12:59:17 PM
[2020-09-09-Agenda-19th TC of EU Executive Steering group + AANTEKENINGEN.docx](#)
[6. Mapping survey on currently available and forecasted \(vaccine\) expertise.pdf](#)
[7. PPT WHO Solidarity for vaccines-.pdf](#)

From: (10)(2e) <(10)(2e)@cbg-meb.nl>
Sent: woensdag 9 september 2020 15:17
To: (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>;
 (10)(2e) @cbg-meb.nl; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) @igj.nl;
 (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e)
 (10)(2e) @minvws.nl; (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@minvws.nl>;
 (10)(2e) @ccmo.nl; (10)(2e) <(10)(2e)@ccmo.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>;
 (10)(2e) @minvws.nl; (10)(2e) <(10)(2e)@minvws.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) @minvws.nl;
 (10)(2e) @cbg-meb.nl; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) @cbg-meb.nl;
 (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>;

Cc: (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>; (10)(2e) <(10)(2e)@cbg-meb.nl>

Subject: COVID-19: verslag EU Executive Steering Group - 9 september 2020

Beste collega's,

Op woensdagochtend 9 september vond een bijeenkomst plaats van de *EU Executive Steering Group (SG) on shortages of medicines caused by major events*.

Hieronder volgt een terugkoppeling van hetgeen daar is besproken.

Bijeenkomst 9 september

In de bijeenkomst van 9 september werden de volgende punten besproken:

Demand forecast for ICU medicines in the EU/EEA in the context of COVID-19

- Ad hoc Working Group discusses comments on demand forecast model.
- Comments from Ireland, Spain and the Netherlands discussed.
- EU SG in general satisfied with content of reflection in terms of methodology proposed.
- Next step: pilot will be launched to see whether the data asked for is manageable by member states.
- Particular attention raised to Dutch concerns regarding the the collecting of supply and demand data; tension with antitrust rules is prevalent in other member states as well. DG Santé had understood previously that some flexibility with regard to competition laws is permissible during a crisis situation, but will explore further with DG Competition.
- Netherlands underlines that any further development of centralized collection of demand and supply data into a structure of a more permanent nature may soon reach its limits – all is based on voluntary cooperation of the parties involved.

Regulatory capacity in the network - launch of the mapping survey on the currently available and the forecasted (vaccine) expertise within the Network

- EMA will launch survey among NCAs on current and forecasted (vaccine) expertise with regard to COVID-19 – and hopes to receive feedback by 21 September 2020.

International randomized trial of candidate vaccines against COVID-19 – The Solidarity Vaccines trial under preparation by WHO

- EC has been asked by WHO to support solidarity vaccine trials.
- WHO has developed a scientific assessment protocol and asks the EMRN to perform a regulatory and scientific assessment of the protocol.

Bijgevoegd vinden jullie ter info:

- Vergaderagenda met aantekeningen
- Belangrijkste onderliggende vergaderstukken.

De volgende bijeenkomst vindt plaats op 23 september 2020.

Voor meer informatie weten jullie mij te bereiken.

Met vriendelijke groet,

(10)(2e)

(10)(2e)

(10)(2e)



Medicines Evaluation Board

(10)(2e) @cbg-meb.nl

(10)(2e)

www.cbg-meb.nl

Graadt van Roggenweg 500 | 3531 AH Utrecht
The Netherlands



GOOD MEDICINES USED BETTER